Compare SPRO & SEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | SEV |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.0M | 63.2M |
| IPO Year | 2017 | 2025 |
| Metric | SPRO | SEV |
|---|---|---|
| Price | $0.94 | $1.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $5.33 | ★ $6.33 |
| AVG Volume (30 Days) | 320.0K | ★ 371.8K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,802,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25,146.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 39.24 | N/A |
| 52 Week Low | $0.95 | $1.29 |
| 52 Week High | $3.08 | $7.00 |
| Indicator | SPRO | SEV |
|---|---|---|
| Relative Strength Index (RSI) | 34.32 | 45.32 |
| Support Level | N/A | $1.51 |
| Resistance Level | $1.27 | $2.06 |
| Average True Range (ATR) | 0.06 | 0.16 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 3.18 | 18.71 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Aptera Motors Corp engages in the development, production, and distribution of energy efficient solar-powered, battery-electric vehicles. The company has designed the Aptera vehicle to provide up to an estimated 40 miles per day by collecting energy from the sun and storing it in its proprietary battery pack. The company operates as a single reportable segment focused on the development of solar electric vehicles.